Published in final edited form as:

Basic Res Cardiol. 2013 March ; 108(2): 335. doi:10.1007/s00395-013-0335-3.

Cardiomyocyte-Specific Deletion of Endothelin Receptor A Rescues Ageing-Associated Cardiac Hypertrophy and Contractile Dysfunction: Role of Autophagy

Asli F. Ceylan-Isik^{1,*}, Maolong Dong^{1,2,*}, Yingmei Zhang^{1,3,*}, Feng Dong¹, Subat Turdi¹, Sreejayan Nair¹, Masashi Yanagisawa⁴, and Jun Ren¹

¹Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, Laramie, WY 82071, USA

²Department of Burn and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China 710032

³Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China 710032

⁴Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Abstract

Cardiac ageing is manifested as cardiac remodeling and contractile dysfunction although precise mechanisms remain elusive. This study was designed to examine the role of endothelin-1 (ET-1) in ageing-associated myocardial morphological and contractile defects. Echocardiographic and cardiomyocyte contractile properties were evaluated in young (5–6 mo) and old (26–28 mo) C57BL/6 wild-type and cardiomyocyte-specific ET_A receptor knockout (ETAKO) mice. Cardiac ROS production and histology were examined. Our data revealed that ETAKO mice displayed an improved survival. Ageing increased plasma levels of ET-1 and Ang II, compromised cardiac function (fractional shortening, cardiomyocyte peak shortening, maximal velocity of shortening/relengthening and prolonged relengthening) and intracellular Ca²⁺ handling (reduced intracellular Ca²⁺ release and decay), the effects of which with the exception of ET-1 and Ang II levels was improved by ETAKO. Histological examination displayed cardiomyocyte hypertrophy and interstitial fibrosis associated with cardiac remodeling in aged C57 mice, which were alleviated in ETAKO mice. Ageing promoted ROS generation, protein damage, ER stress, upregulated GATA4, ANP, NFATc3, and the autophagosome cargo protein p62, downregulated intracellular Ca²⁺ regulatory proteins SERCA2a and phospholamban as well as the autophagic markers Beclin-1, Atg7, Atg5 and LC3BII, which were ablated by ETAKO. ET-1 triggered a decrease in autophagy and increased hypertrophic markers *in vitro* the effect of which were reversed by the ET_A receptor antagonist BQ123 and the autophagy inducer rapamycin. Antagonism of ET_A but not ET_B receptor rescued cardiac ageing, which was negated by autophagy inhibition. Taken together, our data suggest that cardiac ET_A receptor ablation protects against ageing-associated myocardial remodeling and contractile dysfunction possibly through autophagy regulation.

Correspondence should be addressed to: Dr. Jun Ren, Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071, USA, Tel: (307) 766-6131; Fax: (307) 766-2953; jren@uwyo.edu.

*These authors contributed equally to this work.

DISCLOSURES: None.

Keywords

ET_A receptor; myocardial; cardiomyocyte; contraction; morphology; autophagy

INTRODUCTION

Cardiac ageing, an irreversible biological process, is manifested as a drastic decrease in pump function and contractile reserve [23–25]. Ageing-associated cardiac defect *en route* to heart failure is considered to attribute to the high morbidity and mortality in the elderly [25, 49]. A number of theories have been postulated for senescence-induced changes in myocardial function and remodeling including diminution of intrinsic cardiac contractile properties resulted from β -myosin heavy chain reexpression, defective intracellular Ca²⁺ transport by sarcoplasmic reticulum, prolongation of action potential duration, mitochondrial injury, accumulation of free radicals or reactive oxygen species (ROS), deterioration in vascular function, interaction between occult diseases and physical inactivity, as well as loss of ischemic pre- and post-conditioning protection [2–4, 19, 22, 25, 26, 48, 49]. In consequence, aged hearts often display a loss of adaptive capacity in response to mechanical or pathological stresses such as acute ischemia [2, 4]. Recent evidence suggested a rather important role for autophagy, energy metabolism and mitochondrial biogenesis in the onset and progression of cardiac ageing [7, 27, 32, 34, 39, 40]. Nonetheless, the precise pathophysiology of cardiac ageing has not been carefully defined.

Endothelin-1 (ET-1) is a potent vasoconstrictor secreted by endothelium. ET-1 exerts its biological action through its membrane receptors namely ET_A and ET_B [47]. ET_A is abundant in cardiomyocytes whereas ET_B is mostly found in endothelial cells as well as cardiomyocytes [37]. ET-1 is capable of exerting profound cardiovascular effects including regulation of vascular tone, positive inotropic and chronotropic properties as well as cell hypertrophy in the heart [18, 19, 31]. ET-1 may be produced in the heart in response to a variety of stresses including ageing. An ageing-related change in circulating ET-1 levels and ET receptors, similar to that of the well-known vasoconstrictor angiotensin II (Ang II), has been reported [1, 8, 43, 50]. Therefore this study was designed to examine the role of ET-1 cascade in particular ET_A receptor in ageing-induced cardiac remodeling and contractile dysfunction. We took advantage of a murine model of cardiomyocyte-specific ET_A knockout which displays a ~ 80% loss in cardiac ET_A mRNA level [20]. Myocardial histology, contractile and intracellular Ca²⁺ properties were examined in wild-type C57/BL6 and ET_A knockout mice. To elucidate the underlying mechanism(s) involved in ageing and/or ET_A knockout-induced cardiac responses, myocardial autophagy and ROS was examined. Autophagy is a cytoprotective mechanism to remove aberrant or dysfunctional molecules and intracellular organelles [7, 9, 13, 14, 35]. Autophagy is initiated with formation of the double-membrane autophagosomes involving elongation of isolated membrane and maturation of autophagosome followed by infusion of autophagosome with lysosome [7, 9, 10, 14]. To this end, the key autophagy-related genes including beclin-1, Atg5, Atg7, microtubule-associated protein 1 light chain 3 (LC3B or Atg8) and the autophagosome cargo protein p62 were scrutinized in young or old C57/BL6 and ET_A knockout mice. Given the essential role of autophagosome removal in autophagy regulation [14], LC3B and p62 were evaluated in myocytes exposed to exogenous ET-1 in the absence (steady-state autophagosomes) or the presence (cumulative autophagosomes) of a mixture of lysosomal inhibitors. As ET_B receptor becomes the dominant ET-1 receptor in cardiomyocyte-specific ET_A knockout mice where ET_A receptor may be dispensable for cardiac homeostasis [20], *in vivo* treatment of the ET_A antagonist BQ123 and the ET_B receptor antagonist BQ788 was performed in young and old mice prior to mechanical assessment.

MATERIALS and METHODS

Experimental animals, treatment of ET-1 receptor antagonists, and autophagy inhibitor

All animal procedures described here were approved by the Institutional Animal Use and Care Committee at the University of Wyoming (Laramie, WY, USA). The cre/loxP technique was employed to generate mice with the ET_A gene deleted specifically in cardiomyocytes. The cre recombinase transgene driven by the α -myosin heavy-chain promoter deleted the floxed ET_A allele in the heart, resulting in a 78% reduction in cardiac ET_A mRNA levels [20]. Young (4–5 month-old) and old (26–28 month-old) male cardiomyocyte-specific ET_A receptor knockout (ETAKO) and age-/ gender-matched wild-type C57BL/6J mice were used. To examine the effect of ET_A and ET_B receptor antagonism on cardiac ageing, a cohort of young and old C57BL/6J mice were treated with the ET_A receptor antagonist BQ123 or the ET_B receptor antagonist BQ788 (1 mg/kg/d, i.p.) for 28 days [6, 33] in the presence or absence of autophagy inhibitor 3-MA (10 mg/kg, once a week, i.p.) [12]. Mice were maintained on a 12:12-h light-dark illumination cycle with access to food and water *ad libitum*.

Blood pressure, plasma levels ET-1 and Ang II

Systolic, diastolic and mean blood pressures were examined using a KODA semi-automated, amplified tail cuff device (Kent Scientific Corporation, Torrington, CT, USA). Mice were placed in a temperature-controlled restrainer on a warm pad for 30 min before measurements were taken. A mean of three readings was taken as respective blood pressure value. Upon sacrifice, trunk blood was collected in chilled tubes and microfuged at room temperature before the plasma was transferred to ice cold methanol (100%). Plasma ET-1 levels were determined using an ET-1 enzyme immunometric assay kit (Assay Designs, Inc. Ann Arbor, MI, USA) based on a double-antibody sandwich technique [46]. The detection threshold for ET-1 was 0.14 pg/ml. Plasma AngII levels were measured using an ELISA kit (Cayman Chemicals, Ann Arbor, MI, USA) [44]. The detection threshold for Ang II was 1.5 pg/ml.

Echocardiographic assessment

Cardiac geometry and function were evaluated in anesthetized (Avertin 2.5%, 10 μ l/g bw, i.p.) mice using a 2-D guided M-mode Sonos 5500 echocardiography (Phillips Medical Systems, Andover, MD, USA) equipped with a 15-6 MHz linear transducer. Hearts were imaged in 2-D mode in the parasternal long-axis view with a depth of 2 cm. A M-mode cursor was then positioned perpendicular to interventricular septum and posterior wall of the left ventricular (LV) at the level of the papillary muscles in the 2-D mode. The sweep speed was 100 mm/sec at the M-mode. Diastolic wall thickness, LV end diastolic dimension (EDD) and LV end systolic dimension (ESD) were measured from leading edge to leading edge in accordance with the Guidelines of the American Society of Echocardiography [28]. The percentage of LV fractional shortening was calculated as [(EDD-ESD)/EDD] $\times$ 100. Heart rates were averaged over 10 cardiac cycles [16].

Isolation of murine cardiomyocytes

Cardiomyocytes were enzymatically isolated as described [16]. Briefly, hearts were removed and perfused (37°C) with oxygenated (5% CO₂–95% O₂) Krebs–Henseleit bicarbonate (KHB) buffer containing (in mM) 118 NaCl, 4.7 KCl, 1.2 MgSO₄, 1.2 KH₂PO₄, 25 NaHCO₃, 10 HEPES and 11.1 glucose. Hearts were subsequently perfused with a Ca²⁺-free KHB-buffer that containing Liberase Blendzyme (10 mg/ml; Roche, Indianapolis, IN) for 15 min. After perfusion, left ventricles were removed and minced to disperse the individual cardiomyocytes in Ca²⁺-free KHB-buffer. Extracellular Ca²⁺ was added incrementally to 1.25 mM. Myocytes with obvious sarcolemmal blebs or spontaneous

contractions were not used. Only rod-shaped myocytes with clear edges were selected for mechanical or intracellular Ca^{2+} transient studies.

Cell shortening/relengthening

Mechanical properties of cardiomyocytes were assessed using a SoftEdge MyoCam system (IonOptix Corporation, Milton, MA, USA) [16]. Cardiomyocytes were placed in a chamber mounted on the stage of an inverted microscope (Olympus, IX-70) and superfused at 25°C with a buffer containing (in mmol/l): 131 NaCl, 4 KCl, 1 CaCl_2 , 1 MgCl_2 , 10 Glucose and 10 HEPES, at pH 7.4. Cells were field-stimulated with suprathreshold voltage at the frequency of 0.5 Hz unless otherwise stated, with a 3 msec duration, using a pair of platinum wires placed on opposite sides of the chamber and connected to an electrical stimulator (FHC Inc, Brunswick, NE, USA). The myocyte being studied was displayed on a computer monitor using an IonOptix MyoCam camera. IonOptix SoftEdge software was used to capture changes in cell length during shortening and relengthening. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS), maximal velocities of cell shortening and relengthening ($\pm \text{dL/dt}$), time-to-PS (TPS), time-to-90% relengthening (TR_{90}). In the case of altering stimulus frequency, the steady-state contraction of myocyte was achieved (usually after the first six beats) before PS amplitude was recorded at 0.1, 0.5, 1.0, 3.0 and 5.0 Hz.

Intracellular Ca^{2+} transients

Separate cohorts of myocytes were loaded with fura-2/AM (0.5 μM) for 15 min, and fluorescence intensity was measured with a dual-excitation fluorescence photomultiplier system (IonOptix). Myocytes were placed on an inverted Olympus microscope and imaged through a Fluor 40x-oil objective. Cells were exposed to light emitted by a 75 W mercury lamp and passed through either a 360 nm or a 380 nm filter. The myocytes were stimulated to contract at 0.5 Hz. Fluorescence emissions were detected between 480 nm and 520 nm by a photomultiplier tube after cells were first illuminated at 360 nm for 0.5 sec and then at 380 nm for the duration of the recording protocol (333 Hz sampling rate). The 360 nm excitation scan was repeated at the end of the protocol, and qualitative changes in intracellular Ca^{2+} concentration were inferred from the ratio of the fluorescence intensity at two wavelengths. Intracellular Ca^{2+} decay rate was calculated from both single and bi-exponential curve fitting [16].

Histological examination

Hearts were harvested and sliced at mid-ventricular level followed by fixation with normal buffered formalin. Paraffin-embedded transverse sections were cut in 5- μm in thickness and stained with Masson trichrome [11]. Sections were photographed with a 40 $\times$ objective of an Olympus BX-51 microscope equipped with an Olympus MagmaFire SP digital camera. Five random fields from each section (3 sections per mouse) were assessed for fibrosis. To determine fibrotic area, pixel counts of blue stained fibers were quantified using Color range and Histogram commands in Photoshop. Fibrotic area was calculated by dividing the pixels of blue stained area to total pixels of non-white area. For cross-sectional measurement, transverse sections of myocardium were stained with the FITC-conjugated wheat-germ agglutinin [41] and were mounted with Vectashield prior to analysis with NIH ImageJ software.

ROS production

Production of intracellular ROS was evaluated by analyzing the fluorescence intensity resulted from oxidation of the intracellular fluoroprobe 5-(6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (DCF). In brief, cardiomyocytes were loaded with 10

μM DCF at 37°C for 30 min. The fluorescence intensity was measured using a fluorescent microplate reader at an excitation wavelength of 480 nm and an emission wavelength of 530 nm. Untreated cells showed no fluorescence and were used to determine background fluorescence [40].

Protein carbonyl assay

To assess cardiac oxidative damage, the tissue protein carbonyl content was determined as described [11]. Briefly, proteins were extracted and minced to prevent proteolytic degradation. Nucleic acids were eliminated by treating the samples with 1% streptomycin sulfate for 15 min, followed by a 10 min centrifugation ($11,000 \times g$). Protein was precipitated by adding an equal volume of 20% TCA to protein (0.5 mg) and centrifuged for 1 min. The TCA solution was removed and the sample resuspended in 10 mM 2,4-dinitrophenylhydrazine (2,4-DNPH) solution. Samples were incubated at room temperature for 15–30 min. Following a 500 μl of 20% TCA addition, samples were centrifuged for 3 min. The supernatant was discarded, the pellet washed in ethanol:ethyl acetate and allowed to incubate at room temperature for 10 min. The samples were centrifuged again for 3 min and the ethanol:ethyl acetate steps repeated 2 more times. The precipitate was resuspended in 6 M guanidine solution, centrifuged for 3 min and insoluble debris removed. The maximum absorbance (360–390 nm) of the supernatant was read against appropriate blanks (water, 2 M HCl) and the carbonyl content was calculated using the molar absorption coefficient of $22,000 \text{ M}^{-1}\text{cm}^{-1}$.

Western blot analysis

Expression of the essential autophagic markers Beclin-1, Atg 7, Atg 5 and LC3B, the intracellular Ca^{2+} regulatory proteins sarco(endo)plasmic reticulum Ca^{2+} -ATPase isoform 2a (SERCA2a) and phospholamban, the hypertrophic markers GATA4, ANP, NFATc3 and phosphorylated NFATc3 as well as the endoplasmic reticulum stress markers Bip, CHOP and calcineurin were examined by Western blot analysis. The protein was prepared as described [16]. Samples containing equal amount of proteins were separated on 10% SDS-polyacrylamide gels in a minigel apparatus (Mini-PROTEAN II, Bio-Rad) and transferred to nitrocellulose membranes. The membranes were blocked with 5% milk in TBS-T, and were incubated overnight at 4°C with rabbit polyclonal anti-ET_AR (1:1,000), rabbit polyclonal anti-ET_BR (1:1,000), rabbit monoclonal anti-Beclin-1 (1:1,000), rabbit monoclonal anti-Atg7 (1:1,000), rabbit anti-Atg5 (1:1,000), rabbit anti-LC3B (1:1,000), guinea pig polyclonal anti-p62/SQSTM1 (1:1,000), rabbit monoclonal anti-SERCA2a (1:1,000), rabbit monoclonal anti-phospholamban (1:1,000), rabbit polyclonal anti- Na^{+} - Ca^{2+} exchanger, rabbit anti-GATA4 monoclonal (1:1,000), rabbit monoclonal anti-ANP (1:1,000), rabbit monoclonal anti-NFATc3 (1:1,000), rabbit monoclonal anti-pNFATc3 (1:1,000), rabbit anti-Bip monoclonal (1:1,000), mouse monoclonal anti-CHOP (1:1,000), and rabbit monoclonal anti-calcineurin (1:1,000) antibodies. Anti-SERCA2a was purchased from Affinity BioReagents (Golden, CO, USA). Anti-anti-ET_AR and anti-phospholamban antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-ANP antibody was purchased from Santa Cruz (Santa Cruz, CA, USA). All other antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). After immunoblotting, the film was scanned and the intensity of immunoblot bands was detected with a Bio-Rad Calibrated Densitometer. GAPDH was used as the loading control.

ET_A receptor blockage in H9C2 myoblasts

Given the poor viability of murine cardiomyocytes in culture over time, rat embryonic cardiac myoblast cells (H9C2) [15, 17] obtained from ATCC (Manassas, VA, USA) were used for this part of study. Cells were incubated in 6-well plates at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1%

penicillin-streptomycin under a humidified atmosphere with 5% CO₂. Cells were treated with endothelin-1 (ET-1, 10 nM) for 24 hrs in the absence or presence of the ET_A receptor blocker BQ123 or the autophagy inducer rapamycin prior assessment of protein expression.

Statistical analysis

Data were mean $\pm$ SEM. The log rank test was used for Kaplan-Meier survival comparison. Statistical significance ($p < 0.05$) was estimated by a one-way analysis of variance (ANOVA) followed by the Newman-Keuls *post hoc* analysis.

RESULTS

General biometric and echocardiographic properties of C57BL/6 and ETAKO mice

As expected, increased age significantly elevated body and heart weights with lesser effects on liver and kidney weights. The organ sizes of heart, liver and kidney were unaffected by ageing. ET_A receptor knockout did not affect body or organ weights although it significantly alleviated ageing-induced cardiac hypertrophy. Ageing elicited a subtle but significant increase in systolic blood pressure without affecting diastolic and mean blood pressures, the effects of which were unaffected by ET_A knockout. Plasma levels of ET-1 and Ang II were both elevated in ageing groups, the effects of which were unaffected by ET_A knockout. Heart rate and LV EDD were comparable among all groups. While ET_A knockout did not affect wall thickness, LV mass, normalized LV mass, ESD and fractional shortening at young age, it attenuated or mitigated ageing-induced increase in wall thickness, LV ESD, LV mass and normalized LV mass as well as decline in fractional shortening (Table 1). These findings suggest that ET_A knockout ameliorates ageing-induced cardiac remodeling and contractile dysfunction. The Kaplan-Meier curve depicts that ET_A knockout mice display significantly better survival rates than C57BL/6 mice. The median lifespan was 25.2 and 30.3 months for C57BL/6 and ET_A knockout groups, respectively. Survival curves of the two mouse lines begin to separate from each other after ~ 15 months of age with ET_A knockout mice exhibiting a reduced mortality rate (Fig. 1A).

Effects of ET_A knockout on aging-induced changes in ET_A and ET_B receptor expression

As expected, protein levels of ET_A receptor were significantly diminished in hearts from cardiomyocyte-specific ET_A knockout mice. Ageing significantly upregulated expression of ET_A receptor, the effect was blunted in the ET_A knockout mice. Consistent with our earlier report [20], ET_A knockout triggered a subtle but significant increase in ET_B receptor expression. Ageing did not affect the level of ET_B receptor although it removed ET_A knockout-elicited change in ET_B receptor seen at young ages (Fig. 1B–C).

Mechanical and intracellular Ca²⁺ properties of cardiomyocytes

Mechanical properties revealed comparable resting cell length regardless of age or ET_A knockout (data not shown). Ageing significantly reduced peak shortening and maximal velocity of shortening/relengthening ($\pm$ dL/dt), prolonged TR₉₀ associated with similar TPS, the effects of which were attenuated or ablated by ET_A knockout. ET_A knockout itself did not exert any notable effect at young ages (Fig. 2). Given that rodent hearts normally contract at high frequencies, we evaluated the impact of ageing and/or ET_A knockout on cardiac contractile function under higher frequencies (up to 5.0 Hz). Cardiomyocytes were initially stimulated to contract at 0.5 Hz for 5 min to ensure steady-state before commencing the frequency response. Fig. 3 displays a negative staircase of peak shortening amplitude with increased stimulus frequencies in all 4 groups with a steeper decline in aged C57BL/6 mice. Although ET_A knockout did not affect the frequency-peak shortening relationship in young mice, it negated ageing-induced steeper decline in peak shortening with increased

stimulus frequencies. Resting cell length was comparable among all 4 groups at the frequencies tested. These data favor a possible role of improved intracellular Ca^{2+} cycling underneath ET_A knockout-elicited cardioprotection against ageing.

To better understand the mechanism(s) underneath ET_A knockout-offered beneficial effects against cardiac ageing, fura-2 fluorescence was monitored to evaluate intracellular Ca^{2+} handling properties. Cardiomyocytes from aged C57BL/6 mice displayed reduced intracellular Ca^{2+} release in response to electrical stimuli (ΔFFI) and prolonged intracellular Ca^{2+} decay (both single or bi-exponential curve fitting) along with unchanged resting intracellular Ca^{2+} (resting FFI), the effect of which was reconciled by ET_A knockout. ET_A knockout did not alter intracellular Ca^{2+} homeostasis at young ages (Fig. 4).

Effect of ET_A knockout on myocardial histology in aging

To assess the impact of ET_A knockout on myocardial histology in ageing, cardiomyocyte cross-sectional area and interstitial fibrosis were examined. Data from the wheat germ agglutinin staining revealed an increased cardiomyocyte cross-sectional area in ageing, consistent with the higher LV mass and heart weight in aged C57BL/6 mice. ET_A knockout significantly attenuated ageing-induced cardiomyocyte hypertrophy. Likewise, the Masson's trichrome staining revealed overt myocardial interstitial fibrosis in aged C57BL/6 myocardium, the effect of which was significantly dampened by ET_A receptor knockout. Lastly, ET_A knockout did not affect cardiomyocyte cross-sectional area and interstitial fibrosis at young ages (Fig. 5A–D).

Effect of ET_A knockout on aging-induced ROS production and protein carbonyl formation

To examine the potential mechanism of action behind the ET_A receptor knockout-elicited protection against ageing-induced cardiac geometric and contractile anomalies, ROS production was examined in cardiomyocytes from C57BL/6 and ET_A knockout mice at both young and old ages. Results shown in Fig. 5E–F indicate that ROS production was significantly elevated in aged C57BL/6 mouse cardiomyocytes. Consistent with its mechanical and morphometric responses, ET_A knockout attenuated ageing-induced increase in ROS production. Furthermore, ET_A knockout significantly ameliorated ageing-induced protein damage (carbonyl content in nmole/mg protein: C57BL/6-young: 4.09 ± 0.58 ; C57BL/6-old: $10.75 \pm 1.72^*$; ETAKO -young: 3.94 ± 0.59 ; and ETAKO -old: $6.44 \pm 0.49^{* \#}$, * $p < 0.05$ vs. C57BL/6-young; # $p < 0.05$ vs. C57BL/6-old, $n = 5$ –7 hearts). ET_A receptor knockout itself exerted little effects on ROS production and carbonyl formation at young ages, indicating that the genetic manipulation itself is not innately harmful.

Effects of ET_A knockout on intracellular Ca^{2+} regulatory and hypertrophic proteins

Western blot analysis revealed significantly downregulated levels of intracellular Ca^{2+} regulatory proteins SERCA2a and phospholamban in aged C57BL/6 myocardium. ET_A knockout mitigated ageing-induced decrease in SERCA2a and phospholamban as well as SERCA2a-to-phospholamban ratio without eliciting any notable effects by itself. Neither ET_A knockout nor ageing affected the level of Na^+ - Ca^{2+} exchanger. Assessment of cardiac hypertrophic markers revealed that elevated expression of GATA4 and ANP along with increased phosphorylation of NFATc3 in aged C57BL/6 hearts. ET_A receptor knockout significantly attenuated or nullified ageing-induced increase in the levels of GATA4, ANP and phosphorylated NFATc3. Last but not least, ET_A knockout did not affect the levels of GATA4, ANP and phosphorylated NFATc3 at young ages (Fig. 6).

Effects of ET_A knockout on ageing-induced autophagy response

To explore if autophagy contributes to ET_A knockout-offered cardioprotection against ageing, levels of autophagic markers Beclin-1, Atg7, Atg5, LC3B and the autophagosome cargo adaptor p62 were evaluated in young or old C57BL/6 and ET_A knockout mice. Our results depict that ageing significantly downregulated the levels of Beclin-1, Atg7, Atg5 and LC3B II/I ratio while upregulated p62 levels, the effects of which were significantly attenuated or mitigated by ET_A receptor knockout. ET_A knockout failed to alter levels of these autophagic markers at young ages (Fig. 7A–F).

Effects of ET_A knockout on ageing-induced ER stress response

As depicted in Fig. 7G–I, Western blot analysis demonstrated a robust decrease in ER stress proteins including Bip, CHOP and a subtle but significant increase in calcineurin level in aged C57BL/6 hearts. ET_A knockout significantly attenuated or obliterated ageing-induced changes in these ER stress markers. ET_A knockout did not exert any notable effect on the levels of these proteins.

Effect of ET_A receptor blockade on ET-1-induced autophagic and hypertrophic responses in H9C2 myoblasts

To further consolidate ageing and/or ET-1-elicited responses in cardiac autophagy and hypertrophy, Western blot analysis was performed on the essential autophagic and hypertrophic protein markers including Beclin-1, Atg7, Atg5, LC3B and ANP in H9C2 myoblasts incubated with ET-1 (10 nM) for 24 hrs in the absence or presence of the ET_A receptor blocker BQ123 (1 μM) or the autophagy inducer rapamycin (5 μM). Our data shown in Fig. 8 depicted that ET-1 exposure significantly downregulated levels of Beclin-1, Atg7, Atg5 and LC3B II/I ratio, indicative of suppressed autophagic responses. Interestingly, both BQ123 and rapamycin rescued against ET-1-induced loss of autophagy. Both BQ123 and rapamycin triggered a subtle although significant increase in autophagy (as evidenced by Atg7, Atg5 and the steady-state LC3B ratio but not Beclin-1). Meanwhile, ET-1 significantly elevated expression of the hypertrophic markers ANP, GATA4 and phosphorylated NFATc3, the effect of which was attenuated by both BQ123 and rapamycin (Fig. 8 and supplemental Fig. 1). Neither BQ123 nor rapamycin exerted any notable effect on ANP by themselves. Assessment of autophagic flux revealed that lysosomal inhibition partially reversed ET-1-induced decrease in LC3B II/I ratio (cumulative autophagosome formation) without eliciting any effect by itself. Meanwhile, ET-1 and mixed lysosomal inhibitors both significantly upregulated levels of the autophagosome cargo protein p62 without any additive effect between the two.

Effect of ET_A and ET_B antagonism as well as autophagy inhibition on mechanical and intracellular Ca²⁺ properties in cardiomyocytes

To further delineate the potential contribution of ET-1 receptor subtypes and autophagy in cardiac ageing, young and old mice were treated with the ET_A receptor antagonist BQ123 or the ET_B receptor antagonist BQ788 for 4 weeks in the absence or presence of autophagy inhibition using 3-methyladenine (3-MA). Resting cell length was comparable among all groups regardless of ageing or drug treatment. Ageing decreased peak shortening and $\pm$ dL/dt, prolonged TR₉₀ associated with similar TPS, the effects of which obliterated by BQ123 but not BQ788 or 3-MA. Interestingly, 3-MA nullified ET_A receptor antagonism-induced beneficial effect against cardiac ageing. None of the pharmacological inhibitors elicited any notable mechanical effect themselves (Fig. 9). To better understand the mechanism(s) of action behind ET-1 receptor antagonism or autophagy inhibition-induced cardiac mechanical responses, fura-2 fluorescence was monitored to evaluate intracellular Ca²⁺ handling. Consistent with cardiac mechanical responses, the ageing-induced intracellular Ca²⁺

mishandling shown as dampened ΔFFI and prolonged intracellular Ca^{2+} decay (single or bi-exponential curve fitting) along with unchanged resting intracellular Ca^{2+} were significantly improved by BQ123 but not BQ788 or 3-MA. Intriguingly, 3-MA treatment nullified ET_A receptor antagonism-induced beneficial effect against ageing-induced intracellular Ca^{2+} derangement. Last but not least, none of the pharmacological inhibitors employed altered intracellular Ca^{2+} homeostasis themselves (Fig. 10).

DISCUSSION

Myocardial morphometric and functional findings from the present study demonstrated that ET_A receptor knockout significantly attenuated or ablated ageing-induced cardiac geometric and contractile dysfunction. Our data revealed that ET_A receptor knockout significantly ameliorated ageing-induced ROS generation, protein damage, decrease in autophagosome formation and interruption in autophagy flux. The inhibitory of ET-1 on autophagy flux received further support from lysosomal inhibition findings. Our *in vitro* data also depicted that ET-1-induced autophagy and increase in hypertrophic markers GATA4, ANP and phosphorylated NFATc3 may be attenuated or reconciled by the ET_A receptor antagonist BQ123 and the autophagy inducer rapamycin. Shortterm treatment of the ET_A but not ET_B receptor antagonist improved ageing-associated cardiomyocyte mechanical properties, the effect of which was offset by autophagy inhibition. Given that plasma ET-1 levels and ET_A receptor expression are elevated in ageing, our findings supported a pivotal role of ET-1 system in particular ET_A receptor in ageing-associated cardiac geometric and contractile defect. This is supported by a better survival rate of the ET_A knockout mice compared with the C57BL/6 wild-type mice. More importantly, our findings favor a role of autophagy in ageing and ET_A receptor knockout-induced cardiac geometric and functional changes. These findings suggest the potential of ET_A receptor as a target in the treatment of cardiac ageing-related remodeling and contractile defects.

Our data revealed that ageing elicited a subtle although significant rise in systolic blood pressure, consistent with the elevated plasma Ang II levels with ageing and the reported positive correlation between age and blood pressure [30, 43]. Inhibition of the Ang II cascade has been demonstrated to prolong life and retard ageing-associated complications [43]. Our observation that cardiomyocyte-specific ET_A knockout failed to affect age-associated changes in systolic blood pressure and plasma Ang II levels did not favor a major role of blood pressure and Ang II in ET_A knockout-elicited beneficial effects. Changes in myocardial morphology and contractile function have been reported in ageing hearts characterized by cardiac hypertrophy, intracellular Ca^{2+} dysregulation, compromised contractility and prolonged diastolic duration [21, 26, 48, 49]. This is in line with the findings from our study in that echocardiographic and cardiomyocyte contractile parameters are compromised in aged C57BL/6 mice in conjunction with intracellular Ca^{2+} mishandling. Interestingly, ET_A knockout significantly attenuated or nullified ageing-associated cardiac remodeling (increase in wall thickness, LV end systolic diameter, cardiac hypertrophy manifested as increased LV mass, normalized LV mass and cardiomyocyte cross-sectional area), interstitial fibrosis and decreased myocardial contractility (fractional shortening, peak shortening, maximal velocity of shortening/relengthening, prolonged TR_{90}). In addition, ET_A knockout ablated intracellular Ca^{2+} derangement associated with ageing including decreased ΔFFI and prolonged intracellular Ca^{2+} decay rate. Treatment of ET_A but not ET_B receptor antagonist mimicked ET_A receptor knockout-elicited beneficial effects on cardiomyocyte mechanical properties. These observations favor a prominent role of ET-1 signaling cascade in particular ET_A receptor, in cardiac geometric and functional alterations associated with ageing. ET_A knockout attenuated ageing-induced increase in ESD along with the preserved EDD, likely to be responsible for the improved fractional shortening parameter in aged ET_A knockout mice. Myocardial hypertrophy and fibrosis are common

manifestations of ageing heart and may lead to heart failure [5, 29, 36, 42]. Our data revealed that ET_A knockout attenuated ageing-induced changes in LV mass, heart weight, cardiomyocyte size, interstitial fibrosis and hypertrophic markers (ANP, GATA4 and NFATc3 phosphorylation), suggest a beneficial role of antagonism against ET_A receptor against cardiac ageing. In addition, ET_A knockout itself did not alter cardiac geometric and mechanical properties, indicating the genetic manipulation is not innately harmful for the heart.

Several scenarios may be considered with regards to the possible mechanisms behind the beneficial effects of ET_A receptor knockout or antagonism. First, ET_A knockout attenuated ageing-induced ROS production, suggesting a role of ROS scavenging in ET_A knockout-elicited protection against cardiac ageing. Generation of ROS in particular free radicals is known to play a pivotal role in cardiac remodeling and contractile dysfunction in ageing [19, 23, 25, 40, 49]. Second, aged C57BL/6 cardiomyocytes displayed unchanged resting intracellular Ca²⁺ levels, decreased intracellular Ca²⁺ release in response to electrical stimulus and delayed intracellular Ca²⁺ clearance, somewhat in line with our previous reports [26, 48]. Although ET_A knockout or receptor antagonism with BQ123 did not affect intracellular Ca²⁺ homeostasis in young mice, it attenuated or ablated ageing-induced changes in intracellular Ca²⁺. These findings depict that ET_A receptor knockout or inhibition may rescue ageing-induced disruption of intracellular Ca²⁺ handling. This notion is supported by the restored stress tolerance shown as lessened negative peak shortening-frequency in ageing. Loss of SERCA2a and the SERCA2a-to-phospholamban ratio may account for, at least in part, intracellular Ca²⁺ mishandling, prolonged intracellular Ca²⁺ clearance and cardiac relaxation, as well as reduced stress tolerance in ageing hearts although further study is warranted. Third, data from our study also revealed that levels of ER stress markers (Bip and CHOP) were reduced or increased (calcineurin A) in aged C57BL/6 mice, the effect of which was attenuated or ablated by ET_A knockout. Up-to-date, little is known for the correlation between ageing and ER stress in the heart although findings from our study favor a beneficial role of ER stress in ET_A knockout-induced protection against ageing. The increase in calcineurin A in ageing hearts may be due to a compensatory response. Further study is warranted to explore the role of ER stress in cardiac ageing and ET_A knockout-exerted beneficial effects.

Perhaps the most interesting findings from our study were that ET_A knockout attenuated or reversed ageing-induced downregulation of autophagy markers as well as interruption of autophagic flux. ET_A knockout attenuated or reversed aging-induced reduction in the levels of Beclin-1, Atg7, Atg5 and LC3B while partially increasing ageing-induced rise in the autophagosome cargo protein p62. The potential role of autophagy in ET_A knockout-offered cardioprotection in ageing was consolidated by the observation that autophagy inhibition using 3-MA ablated ET_A receptor antagonist BQ123-induced cardioprotective effect against ageing. A number of reports have depicted reduced autophagosome formation or autophagy flux with ageing, which may be speculated to contribute to ageing-associated accumulation of damaged intracellular components in almost all model organisms thus resulting in altered cellular homeostasis and loss of function in ageing [7, 16, 38, 51]. It is likely that the reduced autophagic activity may contribute to the ageing-associated cardiac hypertrophy and contractile dysfunction [9, 45]. Autophagy is well known to antagonize cardiac hypertrophy by increasing protein degradation, which decreases tissue mass. However, the rate of protective autophagy declines with ageing, leading a state where the heart is unable to remove damaged structures resulting garbage accumulation (abnormal intracellular protein aggregates and undigested materials). Reduced autophagy in ageing eventually results in enhanced oxidative stress, decreased ATP production, collapse of cellular catabolic machinery and cell death [9, 45]. In our hands, ageing overtly inhibited initial autophagosome formation (shown as reduced LC3B) despite interrupted lysosomal

degradation (evidenced as elevated p62), the effects of which were partially or completely reversed by ET_A knockout. *In vitro* finding revealed that ET-1 exposure mimicked lysosomal inhibitors in promoting p62 accumulation (Fig. 8H), consolidating the inhibitory effect of ET-1 on autophagic flux. The subtle although significant rise of LC3B elicited by lysosomal inhibitors following ET-1 challenge (Fig. 8G) may be due to rather limited initial autophagosome formation. Our finding suggested that ET_A knockout attenuated or reversed ageing-induced decline in autophagy in conjunction with hypertrophy (gross, histological findings or protein makers GATA4, ANP and pNFATC3). This is in concert with the *in vitro* findings that autophagy inducer rapamycin rescued against ET-1-induced cardiomyocyte hypertrophy in H9C2 myoblasts. Although it is beyond the scope of our current study, several theories have been postulated to contribute to ageing-associated decline in autophagy. First, the slow build-up of the undigested materials such as lipofuscin within lysosomes with age depresses autophagic activity in aged cardiomyocytes and other postmitotic cells [9]. Second, ageing-associated change in the integrity of the autophagosomal-lysosomal network as evidenced by our autophagosome cargo protein p62 data plays an essential role in the regulation of cardiac autophagy in ageing [9, 16]. Last but not least, an ageing-associated decline in AMPK activity in the hearts may also contribute to the reduced autophagy in ageing hearts [40]. Data from our present study indicated that ET-1 suppressed autophagy, the effect of which may be reconciled by the ET_A blocker BQ123. Although ET-1 has not been previously shown to directly regulate autophagy, one recent report indicated that ET-1-associated vascular injury may be alleviated by autophagy induction [52], favoring an inverse relationship between ET-1 levels and autophagic activity, which is also supported by our current findings. Future study is warranted to better elucidate the precise mechanism of action behind ET-1 and ET_A knockout-induced regulation of autophagy and stress in the heart.

Our data revealed an elevated ET_B receptor abundance in ET_A knockout mice at young ages, coinciding with the notion that ET_B receptor may become the dominant ET-1 receptor while ET_A receptor may be dispensable for the maintenance of cardiac homeostasis [20]. However, the lack of responses from the ET_B receptor antagonist BQ788 in cardiac ageing as opposed to that elicited by the ET_A receptor antagonist BQ123 does not favor a role of ET_B receptor in ageing-associated cardiac abnormalities. This is also in line with the upregulated ET_A receptor express with ageing. It is not exactly clear at this point why elevated expression of ET_B receptor is lost with ageing although caution should be taken with regards to the potential role of ET_B receptor in ET-1-associated cardiac ageing responses.

Experimental limitation: Measurement of cardiac contractile performance in isolated cardiomyocytes has been established to provide a fundamental assessment of cardiac function in pathological states. However, as in any study of this nature, caution needs to be taken when correlating cellular findings to whole heart function, as the latter is composed of heterogeneous cell types, including nerve terminals, fibroblasts, and connective tissues. For example, the apparent discrepancy in the degree of reduction of contractile capacity between *in vivo* fractional shortening (~20%) and *in vitro* peak shortening (~ 80% at 5 Hz) may be attributed to different experimental settings.

In summary, our present study provides evidence, for the first time, that ET_A receptor knockout rescues against ageing-induced cardiac hypertrophy and contractile dysfunction. Our data indicated that ROS production and a decline in autophagy (or autophagy flux) are likely involved in ageing- and ET_A receptor knockout-elicited changes in cardiac remodeling and function. Given that ageing may be associated with reduced rate of formation of autophagosome, poor maturation and efficiency of autophagosome-lysosome fusion, as well as dampened proteolytic activity of lysosomes [7], derangement in autophagy

may contribute to cardiac ageing through accumulation of cytosolic protein aggregates and defective mitochondria. Although our study sheds some light on the role of autophagy and autophagy flux in ageing-induced cardiac geometric, functional and intracellular Ca^{2+} defects, the mechanism of action behind ageing-associated defective autophagy and/or autophagy flux, accumulation of damaged mitochondria, and increased ROS generation still deserves further investigation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to thank Miss Haoyu Zhao from University of Wyoming for her assistance in data analysis. This work was supported by NIH/NCRR P20 RR016474 and P20 GM103432.

REFERENCES

1. Afiatpour P, Latifpour J, Takahashi W, Yono M, Foster HE Jr, Ikeda K, Pouresmail M, Weiss RM. Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors. *Naunyn Schmiedebergs Arch Pharmacol*. 2003; 367:462–472. [PubMed: 12700883]
2. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. *Circ Res*. 2008; 102:131–135. [PubMed: 17967780]
3. Boengler K, Konietzka I, Buechert A, Heinen Y, Garcia-Dorado D, Heusch G, Schulz R. Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. *Am J Physiol Heart Circ Physiol*. 2007; 292:H1764–H1769. [PubMed: 17142336]
4. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. *Cardiovasc Res*. 2009; 83:247–261. [PubMed: 19176601]
5. Carneiro-Ramos MS, Diniz GP, Nadu AP, Almeida J, Vieira RL, Santos RA, Barreto-Chaves ML. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. *Basic Res Cardiol*. 2010; 105:325–335. [PubMed: 20155476]
6. Chen Y, Hanaoka M, Droma Y, Chen P, Voelkel NF, Kubo K. Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats. *Eur Respir J*. 2010; 35:904–912. [PubMed: 19897563]
7. Cuervo AM, Bergamini E, Brunk UT, Droge W, Ffrench M, Terman A. Autophagy and aging: the importance of maintaining "clean" cells. *Autophagy*. 2005; 1:131–140. [PubMed: 16874025]
8. Dai DF, Chen T, Johnson SC, Szeto H, Rabinovitch PS. Cardiac aging: from molecular mechanisms to significance in human health and disease. *Antioxid Redox Signal*. 2012; 16:1492–1526. [PubMed: 22229339]
9. De Meyer GR, De Keulenaer GW, Martinet W. Role of autophagy in heart failure associated with aging. *Heart Fail Rev*. 2010; 15:423–430. [PubMed: 20383579]
10. De Meyer GR, Martinet W. Autophagy in the cardiovascular system. *Biochim Biophys Acta*. 2009; 1793:1485–1495. [PubMed: 19152812]
11. Doser TA, Turdi S, Thomas DP, Epstein PN, Li SY, Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. *Circulation*. 2009; 119:1941–1949. [PubMed: 19332462]
12. Doyle A, Zhang G, Abdel Fattah EA, Eissa NT, Li YP. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. *FASEB J*. 2011; 25:99–110. [PubMed: 20826541]
13. Gottlieb RA, Finley KD, Mentzer RM Jr. Cardioprotection requires taking out the trash. *Basic Res Cardiol*. 2009; 104:169–180. [PubMed: 19242643]

14. Gottlieb RA, Mentzer RM. Autophagy during cardiac stress: joys and frustrations of autophagy. *Annu Rev Physiol.* 2010; 72:45–59. [PubMed: 20148666]
15. Granata R, Trovato L, Gallo MP, Destefanis S, Settanni F, Scarlatti F, Brero A, Ramella R, Volante M, Isgaard J, Levi R, Papotti M, Alloatti G, Ghigo E. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. *Cardiovasc Res.* 2009; 83:303–312. [PubMed: 19293247]
16. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. *Basic Res Cardiol.* 2011; 106:1173–1191. [PubMed: 21901288]
17. Hwang JT, Kwon DY, Park OJ, Kim MS. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. *Genes Nutr.* 2008; 2:323–326. [PubMed: 18850225]
18. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. *J Clin Invest.* 1993; 92:398–403. [PubMed: 8326007]
19. Kakarla SK, Fannin JC, Keshavarzian S, Katta A, Paturi S, Nalabotu SK, Wu M, Rice KM, Manzoor K, Walker EM Jr, Blough ER. Chronic acetaminophen attenuates age-associated increases in cardiac ROS and apoptosis in the Fischer Brown Norway rat. *Basic Res Cardiol.* 2010; 105:535–544. [PubMed: 20407780]
20. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, Yanagisawa M. Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. *Mol Cell Biol.* 2003; 23:8226–8232. [PubMed: 14585980]
21. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. *J Biol Chem.* 1995; 270:17513–17520. [PubMed: 7615556]
22. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. *Circulation.* 2003; 107:490–497. [PubMed: 12551876]
23. Lakatta EG. Cardiovascular aging in health. *Clin Geriatr Med.* 2000; 16:419–444. [PubMed: 10918640]
24. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. *Circulation.* 2003; 107:139–146. [PubMed: 12515756]
25. Lakatta EG, Sollott SJ. The "heartbreak" of older age. *Mol Interv.* 2002; 2:431–446. [PubMed: 14993406]
26. Li SY, Du M, Dolence EK, Fang CX, Mayer GE, Ceylan-Isik AF, LaCour KH, Yang X, Wilbert CJ, Sreejayan N, Ren J. Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification. *Aging Cell.* 2005; 4:57–64. [PubMed: 15771609]
27. Ma H, Wang J, Thomas DP, Tong C, Leng L, Wang W, Merk M, Zierow S, Bernhagen J, Ren J, Bucala R, Li J. Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. *Circulation.* 2010; 122:282–292. [PubMed: 20606117]
28. Manning WJ, Wei JY, Katz SE, Litwin SE, Douglas PS. In vivo assessment of LV mass in mice using high-frequency cardiac ultrasound: necropsy validation. *Am J Physiol.* 1994; 266:H1672–H1675. [PubMed: 8184946]
29. Mraiche F, Oka T, Gan XT, Karmazyn M, Fliegel L. Activated NHE1 is required to induce early cardiac hypertrophy in mice. *Basic Res Cardiol.* 2011; 106:603–616. [PubMed: 21359875]
30. Pearson JD, Morrell CH, Brant LJ, Landis PK, Fleg JL. Age-associated changes in blood pressure in a longitudinal study of healthy men and women. *J Gerontol A Biol Sci Med Sci.* 1997; 52:M177–M183. [PubMed: 9158560]

31. Pieske B, Beyermann B, Breu V, Löffler BM, Schlotthauer K, Maier LS, Schmidt-Schweda S, Just H, Hasenfuss G. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium. *Circulation*. 1999; 99:1802–1809. [PubMed: 10199875]
32. Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH, Shulman GI. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. *Cell Metab*. 2007; 5:151–156. [PubMed: 17276357]
33. Rivera A. Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists. *Am J Physiol Cell Physiol*. 2007; 293:C960–C966. [PubMed: 17494628]
34. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. *Cell*. 2011; 146:682–695. [PubMed: 21884931]
35. Schlossarek S, Englmann DR, Sultan KR, Sauer M, Eschenhagen T, Carrier L. Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. *Basic Res Cardiol*. 2012; 107:235. [PubMed: 22189562]
36. Schneider J, Lother A, Hein L, Gilsbach R. Chronic cardiac pressure overload induces adrenal medulla hypertrophy and increased catecholamine synthesis. *Basic Res Cardiol*. 2011; 106:591–602. [PubMed: 21547520]
37. Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. *FEBS Lett*. 1991; 282:103–106. [PubMed: 1851107]
38. Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H. Autophagic degeneration and death of cardiomyocytes in heart failure. *Autophagy*. 2006; 2:212–214. [PubMed: 16874110]
39. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. *Basic Res Cardiol*. 2012; 107:273. [PubMed: 22622703]
40. Turdi S, Fan X, Li J, Zhao J, Huff AF, Du M, Ren J. AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction. *Aging Cell*. 2010; 9:592–606. [PubMed: 20477759]
41. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, Yu Z, Ferrari VA, Lu MM, Xu J, Zhang H, Hui Y, Cheng Y, Petrenko N, Yu Y, FitzGerald GA. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. *Proc Natl Acad Sci U S A*. 2009; 106:7548–7552. [PubMed: 19376970]
42. Wei JY. Age and the cardiovascular system. *N Engl J Med*. 1992; 327:1735–1739. [PubMed: 1304738]
43. Wray DW, Nishiyama SK, Harris RA, Richardson RS. Angiotensin II in the elderly: impact of angiotensin II type 1 receptor sensitivity on peripheral hemodynamics. *Hypertension*. 2008; 51:1611–1616. [PubMed: 18413487]
44. Xia H, Suda S, Bindom S, Feng Y, Gurley SB, Seth D, Navar LG, Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. *PLoS One*. 2011; 6:e22682. [PubMed: 21818366]
45. Xie M, Morales CR, Lavandero S, Hill JA. Tuning flux: autophagy as a target of heart disease therapy. *Curr Opin Cardiol*. 2011; 26:216–222. [PubMed: 21415729]
46. Xu H, Duan J, Dai S, Wu Y, Sun R, Ren J. alpha-Zearalanol attenuates oxLDL-induced ET-1 gene expression, ET-1 secretion and redox-sensitive intracellular signaling activation in human umbilical vein endothelial cells. *Toxicol Lett*. 2008; 179:163–168. [PubMed: 18579320]
47. Yamamoto S, Matsumoto N, Kanazawa M, Fujita M, Takaoka M, Garipey CE, Yanagisawa M, Matsumura Y. Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts. *Circulation*. 2005; 111:302–309. [PubMed: 15642760]
48. Yang X, Doser TA, Fang CX, Nunn JM, Janardhanan R, Zhu M, Sreejayan N, Quinn MT, Ren J. Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress. *FASEB J*. 2006; 20:1024–1026. [PubMed: 16585059]
49. Yang X, Sreejayan N, Ren J. Views from within and beyond: narratives of cardiac contractile dysfunction under senescence. *Endocrine*. 2005; 26:127–137. [PubMed: 15888924]

50. Yono M, Latifpour J, Takahashi W, Pouresmail M, Afiatpour P, Weiss RM. Age-related changes in the properties of the endothelin receptor system at protein and mRNA levels in the rat vas deferens. *J Recept Signal Transduct Res.* 2004; 24:53–66. [PubMed: 15344879]
51. Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. *Nat Med.* 2008; 14:959–965. [PubMed: 18690243]
52. Zhang YL, Cao YJ, You SJ, Li RX, Liu HH, Liu CF. Protective effects of autophagy against oxidized LDL-induced injury in endothelial cells. *Zhonghua Yi Xue Za Zhi.* 2010; 90:2792–2796. [PubMed: 21162920]

Fig. 1. Cumulative survival curve (Kaplan-Meier survival plot), myocardial levels of ET_A and ET_B receptors in C57BL/6 and ETAKO mice. A: The cumulative survival rate was plotted against age in months; B: ET_A receptor; and C: ET_B receptor; Insets: Representative gel blots depicting expression of ET_A and ET_B receptors (GAPDH used as loading control) using specific antibodies; Mean $\pm$ SEM, Log rank test was performed for Kaplan-Meier curve; $n = 34$ and 28 mice for C57BL/6 and ETAKO mice, respectively (panel A); $n = 4-6$ mice for panels B and C, * $p < 0.05$ vs. C57BL/6 young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 2.

Cardiomyocyte contractile properties in young or old C57BL/6 and ETAKO mice. A: Representative cell shortening traces in young or old C57BL/6 and ETAKO groups; B: Peak shortening (PS) amplitude; C: Maximal velocity of shortening ($+dL/dt$); D: Maximal velocity of relengthening ($-dL/dt$); E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR_{90}). Mean $\pm$ SEM, n = a total of 104 cells from 4 mice per group (panel B–F), * $p < 0.05$ vs. corresponding young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 3. Influence of stimulus frequency (0.1 – 5.0 Hz) on peak shortening (PS) amplitude of cardiomyocytes from young or old C57BL/6 and ETAKO mice. PS at each stimulus frequency was normalized to that of 0.1 Hz from the same cell. A: Resting cell length; B: Change in PS from that of 0.1 Hz from the same cell. Mean $\pm$ SEM, n = a total of 24 – 27 cells from 4 mice per group, * $p < 0.05$ vs. corresponding young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 4. Intracellular Ca^{2+} property of cardiomyocytes from young or old C57BL/6 and ETAKO mice. A-B: Representative intracellular Ca^{2+} transients in young or old C57BL/6 and ETAKO mice; C: Resting fura-2 fluorescence intensity (FFI); D: Change of intracellular Ca^{2+} in response to electrical stimuli (ΔFFI); E: Intracellular Ca^{2+} transient decay rate (single exponential); and F: Intracellular Ca^{2+} transient decay (bi-exponential). Mean $\pm$ SEM, n = a total of 65 – 66 cells from 4 mice per group, * $p < 0.05$ vs. corresponding young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 5. Histological feature and ROS production from young or old C57BL/6 and ETAKO mice. A and C: Representative images of myocardium stained with wheat germ agglutinin (WGA, panel A, original magnification x400) and Masson's trichrome (Panel B, original magnification x200) depicting cardiomyocyte cross-sectional area (CSA) and interstitial fibrosis, respectively; B and D: Quantitative analysis of CSA and interstitial fibrosis using measurements of ~ 160 myocytes from 5–6 mice per group. E: Representative DCF fluorescent images (400x) showing ROS generation in cardiomyocytes from C57BL/6 and ETAKO mice; and F: Pooled data of ROS using DCF fluorescence from 6 isolations per

group. Mean $\pm$ SEM, * $p < 0.05$ vs. corresponding young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 6. Changes of intracellular Ca²⁺ regulating and hypertrophic proteins in myocardium from young or old C57BL/6 and ETAKO mice. **A:** Representative gel blots depicting expression of SERCA2a, phospholamban, Na⁺-Ca²⁺ exchanger, GATA4, phosphorylated NFATc3 (pNFATc3), ANP and GAPDH (loading control) using specific antibodies; **B:** SERCA2a; **C:** Phospholamban; **D:** SERCA2a-to-Phospholamban ratio; **E:** Na⁺-Ca²⁺ exchanger; **F:** GATA4; **G:** ANP and **H:** pNFATc3. Mean ± SEM, n = 5–7, *p < 0.05 vs. corresponding young group; #p < 0.05 vs. C57BL/6 old group.

Fig. 7. Changes of autophagic and ER stress protein markers in myocardium from young or old C57BL/6 and ETAKO mice. **A:** Representative gel blots depicting expression of Beclin-1, Atg5, Atg7, LC3B, p62, Bip, CHOP, Calcineurin A and GAPDH (loading control) using specific antibodies; **B:** Beclin-1; **C:** Atg5; **D:** Atg7; **E:** LC3B-II-to-LC3B-I ratio; **F:** p62; **G:** Bip; **H:** CHOP; and **I:** Calcineurin A. Mean $\pm$ SEM, $n = 4-6$, * $p < 0.05$ vs. corresponding young group; # $p < 0.05$ vs. C57BL/6 old group.

Fig. 8.

Changes of autophagic and hypertrophic markers in H9C2 myoblasts. H9C2 cells were exposed to endothelin-1 (ET-1, 10 nM) for 24 hrs in the absence or presence of the ET_A receptor blocker BQ123 (1 μ M), the autophagy inducer rapamycin (RAP, 5 μ M) or a mixed lysosomal inhibitors [bafilomycin A1 (50 nM), E64D (2.5 μ g/ml), and pepstatin A methyl ester (5 μ g/ml)]. A: Representative gel blots depicting Beclin-1, Atg7, Atg5, LC3B, ANP and GAPDH (loading control) using specific antibodies; B: Beclin-1; C: Atg 7; D: Atg5; E: LC3B II/I ratio (steadystate autophagosomes); F: ANP; G: LC3B II/I ratio (cumulative autophagosomes) in response to ET-1 in the presence or absence of lysosomal inhibitors;

and H: p62 in response to ET-1 in the presence or absence of lysosomal inhibitors. Mean $\pm$ SEM, n = 4–6, *p < 0.05 vs. control (Cont); #p < 0.05 vs. ET-1 group.

Fig. 9.

Cardiomyocyte mechanical properties in young (4-mo) or old (26-mo) C57BL/6 mice treated with or without the ET_A receptor antagonist BQ123 or the ET_B receptor antagonist BQ788 (1 mg/kg/d, i.p.) for 28 days in the presence or absence of autophagy inhibitor 3-MA (10 mg/kg/week, i.p. for 4 weeks). A: Resting cell length; B: Peak shortening (PS) amplitude; C: Maximal velocity of shortening (+dL/dt); D: Maximal velocity of relengthening (−dL/dt); E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR₉₀). Mean $\pm$ SEM, $n = 65\text{--}66$ cells per group, * $p < 0.05$ vs. young group; # $p < 0.05$ vs. old group, † $p < 0.05$ vs. old-BQ123 group.

Fig. 10.

Intracellular Ca^{2+} handling properties in young (4-mo) or old (26-mo) C57BL/6 mice treated with or without the ET_A receptor antagonist BQ123 or the ET_B receptor antagonist BQ788 (1 mg/kg/d, i.p.) for 28 days in the presence or absence of autophagy inhibitor 3-MA (10 mg/kg/week, i.p. for 4 weeks). A: Resting fura-2 fluorescence intensity (FFI); B: Change of intracellular Ca^{2+} in response to electrical stimuli (Δ FFI); C: Intracellular Ca^{2+} transient decay rate (single exponential); and D: Intracellular Ca^{2+} transient decay (bi-exponential). Mean $\pm$ SEM, $n = 61$ cells per group, * $p < 0.05$ vs. young group; # $p < 0.05$ vs. old group, † $p < 0.05$ vs. old-BQ123 group.

Table 1

Biometric and echocardiographic properties in C57 and ETAKO young and old mice

	C57BL/6 Young	C57BL/6 Old	ETAKO Young	ETAKO old
Body Weight (g)	25.3 ± 0.9	29.5 ± 0.5 [*]	25.7 ± 0.8	29.2 ± 0.4 [*]
Heart Weight (mg)	218 ± 14	256 ± 10 [*]	224 ± 14	232 ± 11 [#]
HW/BW (mg/g)	8.60 ± 0.42	8.76 ± 0.41	8.55 ± 0.54	8.01 ± 0.41
Liver Weight (g)	1.32 ± 0.04	1.40 ± 0.03	1.33 ± 0.04	1.41 ± 0.01
LW/BW (mg/g)	48.8 ± 1.3	47.1 ± 1.8	48.8 ± 1.3	48.6 ± 0.8
Kidney Weight (g)	0.39 ± 0.03	0.43 ± 0.01	0.39 ± 0.02	0.40 ± 0.02
KW/BW (mg/kg)	14.3 ± 0.7	14.3 ± 0.6	14.2 ± 0.7	14.1 ± 0.5
Diastolic blood pressure (mmHg)	85.7 ± 2.7	81.3 ± 2.4	84.6 ± 2.6	82.1 ± 1.9
Systolic blood pressure (mmHg)	114.8 ± 2.1	124.7 ± 2.4 [*]	114.3 ± 2.3	122.3 ± 2.1 [*]
Mean blood pressure (mmHg)	95.4 ± 2.0	95.8 ± 1.6	93.8 ± 2.6	95.5 ± 1.3
Plasma ET-1 (pg/ml)	0.96 ± 0.08	2.59 ± 0.20 [*]	0.99 ± 0.11	2.44 ± 0.20 [*]
Plasma Angiotensin II (pg/ml)	105.8 ± 11.0	160.1 ± 12.2 [*]	103.1 ± 7.0	145.5 ± 13.7 [*]
Heart Rate (beat per minute)	453 ± 20	451 ± 23	467 ± 26	442 ± 19
Diastolic Diameter (mm)	2.63 ± 0.14	2.61 ± 0.06	2.68 ± 0.09	2.64 ± 0.05
Systolic Diameter (mm)	1.42 ± 0.08	1.65 ± 0.06 [*]	1.42 ± 0.06	1.45 ± 0.05 [#]
Diastolic Wall Thickness (mm)	0.74 ± 0.05	1.01 ± 0.04 [*]	0.76 ± 0.04	0.80 ± 0.05 [#]
LV Mass (mg)	50.0 ± 5.6	70.5 ± 5.0 [*]	52.0 ± 4.1	57.9 ± 5.0 [#]
Normalized LV Mass (mg/g)	2.07 ± 0.16	2.49 ± 0.19 [*]	2.19 ± 0.13	2.02 ± 0.19 [#]
Fractional Shortening (%)	45.7 ± 1.6	36.7 ± 1.3 [*]	46.7 ± 2.2	44.8 ± 2.3 [#]

HW: heart weight; LW: Liver weight; KW: Kidney weight. Mean ± SEM, n = 13–14 mice per group,

^{*} p < 0.05 vs. corresponding young group;[#] p < 0.05 vs. C57BL/6 old group.